Last edition
News about "SKNY-1"
MIRA Secures Shareholder Approval to Acquire SKNY
The acquisition strengthens MIRA’s pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30 percent weight loss and nicotine craving reversal in preclinical studies.
SKNY-1 | 13/09/2025 | By Dineshwori | 119
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members